Antonio Llombart-Cussac, MD, Ph.D. founding partner of Medica Scientia Innovation Research (MedSIR) and the Hospital Arnau de Vilanova explains the SABCS 2020 Abstract – A Phase II Proof-of-Concept Study of Palbociclib Rechallenge in Patients with HR+HER2- Metastatic Breast Cancer and Clinical Benefit to Prior Palbociclib-Based Treatment BIOPER.
Abstract –
BIOPER was a multicenter, open-label, non-controlled phase II trial with two co-primary objectives: I To evaluate the clinical benefit of palbociclib plus endocrine therapy in patients with metastatic breast cancer who have previously received hormone therapy in combination with palbociclib and who have achieved clinical benefit after progression of the disease; (ii) To investigate a molecular profile capable of identifying hormone therapy in combination with palbociclib Dr. Antonio Llombart-Cussac, Head of the Medical Oncology Service at the Arnau de Vilanova Hospital (Valencia, Spain), will report the findings of this relevant study during the poster session at SABCS. The BIOPER study findings will help to understand the best treatment options for patients with breast cancer who stop responding to palbociclib therapy and contribute to personalizing the treatment of patients according to their specific characteristics.